Single High Intensity Focused Ultrasound Session as a Whole Gland Primary Treatment for Clinically Localized Prostate Cancer: 10-Year Outcomes

Table 3

Univariate and multivariable analysis of factors affecting biochemical recurrence free survival in 108 patients.

	Univariate			Multivariate
	OR	95% CI	𝑃 value	OR	95% CI	𝑃 value
Age (per 10 years)	0.95	0.51–1.76	0.87	—	—	—
Gleason score (<7; ≥7)	2.01	1.15–3.51	0.01	1.79	1.04–3.08	0.01
Prostate volume (per 10 mL)	1.29	0.74–2.22	0.37	—	—	—
Pretherapeutic PSA (per ng/mL)	1.06	1.04–1.09	<0.0001	1.08	1.05–1.11	<0.0001
PSA nadir (per ng/mL)	1.92	1.58–2.33	<0.0001	1.87	1.54–2.27	<0.0001
ADT before HIFU (yes v/s no)	1.56	0.92–2.62	0.1	—	—	—
D'Amico risk group (low v/s intermediate)	1.64	0.83–3.24	0.15	—	—	—
D'Amico risk group (low v/s high)	3.36	1.61–7.03	0.001	2.9	1.43–5.89	0.003

OR: odds ratio; CI: confidence interval; PSA: prostate-specific antigen; ADT: androgen deprivation therapy; HIFU: high intensity focused ultrasound.